Technology assessment for new oncology drugs

Clinical Cancer Research

Volumn 19, Issue 1, 2013, Pages 6-11

  Jönsson, Bengt ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOCETAXEL; ERLOTINIB; GEFITINIB; PEMETREXED; TAMOXIFEN; TRASTUZUMAB;

CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG APPROVAL; EUROPE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84871944191     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1819     Document Type: Review

References (23)

1. Jönsson B, Wilking N.Aglobal comparison regarding patient access to cancer drugs. Ann Oncol 2007:18 Suppl 3: iii1-iii77.
2. Drummond M, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Intl J Technol Assessment Health Care 2008;24:244-58.
3. Available from: www.nice.org.uk. [Cited 2012 Aug 5.]
4. Available from: http://www.eunethta.eu. [Cited 2012 Aug 5].
5. O'Neill P, Devlin N. An analysis of NICE's restricted (or 'optimised') decisions. Pharmacoeconomics 2010;28:987-93.
6. Backhouse ME, Wonder M, Hornby E, Kilburg A, Drummond M, Mayer FK. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value Health 2011;14:608-15.
7. Jönsson B. Relative effectiveness and the European pharmaceutical market. Eur J Health Econ 2011;12:97-112.
8. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010;96:179-90.
9. Luce B, Drummond M, Dubois RW, Neumann PJ, Jönsson B, Siebert U, et al. Principles for planning and conducting comparative effectiveness research. J Comparative Effectiveness Res 2012;1:431-40.
10. Sculpher M, Claxton K. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods. Health Econ 2010;19:1132-6.
11. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical interventions. Eur J Health Econ 2009;10:357-359.
12. Devlin NJ, Sussex J. Incorporating multiple criteria in HTA: methods and processes. London: Office of Health Economics; 2011.
13. Devlin N, Dakin H, Rice N, Parkin D, O'Neill P. The influence of cost-effectiveness and other factors on NICE decisions. Paper presented at the Health Economics Research Group; University of York. 2011 Jan 5-7.
14. Appraising life-extending, end of life treatments. [cited 2012 Aug 4]. Available from: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL. pdf.
15. Garau M, Shah KK, Mason A, Wang Q, Towse A, Drummond MF. Using QALYs in cancer: A review of the methodological limitations. Pharmacoeconomics 2011;29:673-85.
16. Meropol NJ, Schulman KA. Cost of cancer: issues and implications. J Clin Oncol 2007;25:180-6.
17. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/ targeted. [Cited 2012 Aug 5.]
18. Gaultney JG, Sanhueza E, Janssen JJ, Redekop WK, Uyl-de Groot CA. Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukaemia. Pharmacogenomics 2011;12:411-21.
19. Lidgren M, Jonsson B, Rehnberg C, Wilking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-95.
20. Davies A, Briggs A, Schneider J, Levy A, Ebeid O, Wagner S, et al. The ends justify the mean: outcome measures for estimating the value of new cancer therapies. Health Outcomes Res Med 2012;3:e25-e36.
21. Latimer N. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. [Cited 2012 Aug 5.] Available from: http://www.nicedsu.org.uk.
22. Booth CM, Elizabeth A, Eisenhauer EA. Progression free survival: Meaningful or simply measurable. J Clin Oncol 2012;30:1030-3.
23. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health 2012;15:570-9.